Also considered
20 papers judged, 2 emailed · Read the digest →
Randomized phase 2 trial in high-volume metastatic hormone-naive prostate cancer, published in Nature Medicine. Adding talazoparib to enzalutamide met its primary PSA response endpoint but with more toxicity, including serious myeloid neoplasms, so it informs PARP-inhibitor combinations in this setting.
Retrospective real-world EHR cohort in chemotherapy- and ARPI-naïve metastatic castration-resistant prostate cancer, published in Cancer Medicine. Suggests enzalutamide is associated with longer survival and treatment duration than abiraterone, which may inform first-line ARPI choice despite observational limitations.
Post hoc quality-adjusted survival (Q-TWiST) analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer, published in Eur J Cancer. Supports the net clinical benefit of adding darolutamide to ADT plus docetaxel despite added time with toxicity.
Single-arm, nonrandomized phase 2 trial of neoadjuvant stereotactic ablative radiotherapy before nephrectomy and IVC thrombectomy in RCC with tumor thrombus, published in JAMA Oncology. Explores feasibility and safety of a new neoadjuvant local approach, but it is early and not practice-changing for systemic therapy.
Retrospective biomarker analysis of the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer, published in JCO Precision Oncology. Plasma genomic instability status was associated with rucaparib outcomes beyond BRCA/PALB2 status, which could help refine PARP inhibitor patient selection.
Narrative review in Cancers of phase II/III data on sequencing radioligand therapy, PARP inhibitors, and ADCs in ARPI-pre-exposed mCRPC. Notes no prospective sequencing trial exists and proposes a hypothesis-generating framework guided by HRR status and PSMA-PET.
Narrative review of randomized and real-world evidence for apalutamide across advanced prostate cancer, published in Expert Review of Anticancer Therapy. Concludes benefit is established in current indications, while deep PSA response-guided de-intensification remains investigational and needs prospective validation.
Retrospective cohort of patients with advanced prostate cancer receiving Lu-177 PSMA-617, published in Frontiers in Oncology. Response and survival did not differ by baseline PET tracer, while higher SUVmean was associated with PSA response, suggesting either tracer can be used for patient selection.
Retrospective single-center study in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA radioligand therapy, published in Eur Urol Oncol. Machine learning models using PET radiomics and clinical data to predict survival; hypothesis-generating and not yet ready to guide treatment selection.
Systematic review and meta-analysis of phase 3 randomized trials of ARPI-intensification regimens in prostate cancer, published in BMC Cancer. Finds a modest increase in neutropenia risk, informing toxicity monitoring with ARPI combinations.
Dutch registry-based retrospective cohort in bone-metastatic castration-resistant prostate cancer, published in JNCI. Shows bone health agent use has declined with infrequent guideline-recommended timing, highlighting a gap in supportive care for an older, more pretreated population.
Secondary dosing, safety and pharmacokinetic analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer, published in Clinical Genitourinary Cancer. Suggests adding darolutamide does not compromise docetaxel delivery or exposure, reassuring for triplet therapy.
Secondary and exploratory analysis of the randomized phase 2 LUNAR trial in oligorecurrent hormone-sensitive prostate cancer, published in European Urology. Extended follow-up supports the benefit of neoadjuvant 177Lu-PNT2002 before SBRT, though it remains an investigational approach.
Translational study in metastatic renal cell carcinoma, published in J Immunother Cancer, analyzing tumor transcriptomics from an SBRT trial with validation in two checkpoint-inhibitor cohorts. Suggests SBRT boosts humoral immune features linked to immunotherapy response, supporting rationale for SBRT-ICB combinations pending trial data.
Retrospective multinational cohort of repeated PSMA PET-guided metastasis-directed radiotherapy in oligorecurrent hormone-sensitive prostate cancer, published in Radiotherapy and Oncology. Suggests repeated MDRT can defer androgen deprivation in selected patients and offers a risk model for patient selection, though it is non-randomized.
Retrospective real-world biomarker study of tumor-informed ctDNA dynamics in advanced urothelial cancer on first-line enfortumab vedotin plus pembrolizumab, published in JCO Precision Oncology. ctDNA clearance tracked with better survival, suggesting a possible response-monitoring tool, though the cohort is small and needs validation.
Large retrospective clinicogenomic cohort analysis of cancer cachexia episodes, published in Nature Medicine. Links cachectic weight loss to progression, outcomes and tumor genotypes and offers a validated risk prediction model in lung, colorectal and prostate cancer, but does not directly guide systemic therapy choices.
Retrospective real-world EHR cohort of patients with metastatic androgen pathway inhibitor-resistant prostate cancer receiving Lu-177 PSMA, published in JAMA Netw Open. Informs treatment sequencing by line and timing of taxane, though evidence is observational.
Propensity-matched real-world analysis in metastatic castration-resistant prostate cancer, published in Clinical Genitourinary Cancer. Suggests Radium-223 carries a higher risk of severe cytopenias than 177Lu-PSMA-617, which may inform radioligand selection and hematologic monitoring.
Narrative review in Cancers (Basel) of cytoreductive radical prostatectomy in oligometastatic prostate cancer, including the robotic approach. Notes that randomized evidence is limited and early-terminated, so benefit remains unproven and selection is critical.